123 related articles for article (PubMed ID: 16275653)
1. Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma.
Ogawa Y; Hotta T; Tobinai K; Watanabe T; Sasaki Y; Minami H; Morishima Y; Ogura M; Seriu T
Ann Oncol; 2006 Feb; 17(2):330-3. PubMed ID: 16275653
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma.
Tobinai K; Watanabe T; Ogura M; Morishima Y; Ogawa Y; Ishizawa K; Minami H; Utsunomiya A; Taniwaki M; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Hayashi M; Seriu T; Hotta T
J Clin Oncol; 2006 Jan; 24(1):174-80. PubMed ID: 16330664
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.
Foran JM; Oscier D; Orchard J; Johnson SA; Tighe M; Cullen MH; de Takats PG; Kraus C; Klein M; Lister TA
J Clin Oncol; 1999 May; 17(5):1574-9. PubMed ID: 10334546
[TBL] [Abstract][Full Text] [Related]
4. The bioavailability of oral fludarabine phosphate is unaffected by food.
Oscier D; Orchard JA; Culligan D; Cunningham D; Johnson S; Parker A; Klein M; Gieschen H
Hematol J; 2001; 2(5):316-21. PubMed ID: 11920267
[TBL] [Abstract][Full Text] [Related]
5. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
Hagenbeek A; Eghbali H; Monfardini S; Vitolo U; Hoskin PJ; de Wolf-Peeters C; MacLennan K; Staab-Renner E; Kalmus J; Schott A; Teodorovic I; Negrouk A; van Glabbeke M; Marcus R
J Clin Oncol; 2006 Apr; 24(10):1590-6. PubMed ID: 16575010
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.
Tobinai K; Ishizawa K; Ogura M; Itoh K; Morishima Y; Ando K; Taniwaki M; Watanabe T; Yamamoto J; Uchida T; Nakata M; Terauchi T; Nawano S; Matsusako M; Hayashi M; Hotta T
Cancer Sci; 2009 Oct; 100(10):1951-6. PubMed ID: 19594547
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine phosphate therapy of non-Hodgkin's lymphoma.
Hochster H; Cassileth P
Semin Oncol; 1990 Oct; 17(5 Suppl 8):63-5. PubMed ID: 1699284
[TBL] [Abstract][Full Text] [Related]
8. The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
Rao R; Shammo JM; Enschede SH; Porter C; Adler SS; Venugopal P; Gregory SA
Clin Lymphoma; 2005 Jun; 6(1):26-30. PubMed ID: 15989703
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
Rossi JF; van Hoof A; de Boeck K; Johnson SA; Bron D; Foussard C; Lister TA; Berthou C; Kramer MH; Littlewood TJ; Marcus RE; Deconinck E; Montillo M; Guibon O; Tollerfield SM
J Clin Oncol; 2004 Apr; 22(7):1260-7. PubMed ID: 15051774
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.
Decaudin D; Bosq J; Tertian G; Nedellec G; Bennaceur A; Venuat AM; Bayle C; Carde P; Bendahmane B; Hayat M; Munck JN
J Clin Oncol; 1998 Feb; 16(2):579-83. PubMed ID: 9469344
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ohmachi K; Ando K; Ogura M; Uchida T; Itoh K; Kubota N; Ishizawa K; Yamamoto J; Watanabe T; Uike N; Choi I; Terui Y; Usuki K; Nagai H; Uoshima N; Tobinai K;
Cancer Sci; 2010 Sep; 101(9):2059-64. PubMed ID: 20626754
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
Chun HG; Leyland-Jones B; Cheson BD
J Clin Oncol; 1991 Jan; 9(1):175-88. PubMed ID: 1702143
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.
Redman JR; Cabanillas F; Velasquez WS; McLaughlin P; Hagemeister FB; Swan F; Rodriguez MA; Plunkett WK; Keating MJ
J Clin Oncol; 1992 May; 10(5):790-4. PubMed ID: 1373760
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study.
Lichtman SM; Etcubanas E; Budman DR; Eisenberg P; Zervos G; D'Amico P; O'Mara V; Musgrave K; Cascella P; Melikian A; Hinderling PH; Ferrer JM; Williams GJ
Cancer Invest; 2002; 20(7-8):904-13. PubMed ID: 12449721
[TBL] [Abstract][Full Text] [Related]
15. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
16. [The use of fludarabine phosphate (Fludara) to treat chronic B-cell lymphocytic leukemia and non-Hodgkin's lymphoma resistant to standard chemotherapy].
Gershanovich ML; Zaritskiĭ AIu; Medvedeva NV; Abdulkadyrov KM; Samuskevich IG; Beresneva IA
Vopr Onkol; 1998; 44(6):696-700. PubMed ID: 10087967
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ogura M; Uchida T; Taniwaki M; Ando K; Watanabe T; Kasai M; Matsumoto Y; Shimizu D; Ogawa Y; Ohmachi K; Yokoyama H; Tobinai K;
Cancer Sci; 2010 Sep; 101(9):2054-8. PubMed ID: 20594195
[TBL] [Abstract][Full Text] [Related]
18. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
19. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia.
Boogaerts MA; Van Hoof A; Catovsky D; Kovacs M; Montillo M; Zinzani PL; Binet JL; Feremans W; Marcus R; Bosch F; Verhoef G; Klein M
J Clin Oncol; 2001 Nov; 19(22):4252-8. PubMed ID: 11709569
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
